<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01646398</url>
  </required_header>
  <id_info>
    <org_study_id>B1851088</org_study_id>
    <nct_id>NCT01646398</nct_id>
  </id_info>
  <brief_title>A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older</brief_title>
  <official_title>A Phase 3, Randomized, Modified Double-Blind, Active-Controlled Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine In Japanese Elderly Adults Aged 65 Years Old And Older Who Are Naive To Pneumococcal Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and immunogenicity of a
      single dose of 13-valent pneumococcal conjugate vaccine compared to a single dose of
      23-valent pneumococcal polysaccharide vaccine in Japanese adults aged 65 years old and older.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for 12 Common Serotypes 1 Month After Vaccination</measure>
    <time_frame>One month after vaccination</time_frame>
    <description>Antibody-mediated serum OPA against each of the 12 pneumococcal serotypes (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) was measured centrally using a quantitative functional microcolony OPA (mcOPA) assay. Results were expressed as OPA titers. OPA titers were logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving At Least a 4-fold Rise in OPA Titers for Serotype 6A 1 Month After Vaccination</measure>
    <time_frame>One month after vaccination</time_frame>
    <description>For serotype 6A the percentage of participants achieving at least a 4-fold rise on the serotype-specific antibody titer from pre-vaccination to 1 month post-vaccination was computed along with exact, 2-sided 95% confidence interval for the proportion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for 12 Common Serotypes and Serotype 6A 1 Month After Vaccination</measure>
    <time_frame>One month after vaccination</time_frame>
    <description>Antibody-mediated serum OPA against each of the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) was measured centrally using a quantitative functional microcolonoy OPA (mcOPA) assay. Results were expressed as OPA titers. OPA titers were logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination</measure>
    <time_frame>Within 14 days after vaccination</time_frame>
    <description>Local reactions reported using an electronic diary. Redness and swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters [cm]; Moderate (5.1 to 10.0 cm); Severe (&gt;10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination</measure>
    <time_frame>Within 14 days after vaccination</time_frame>
    <description>Systemic events reported using an electronic diary. Systemic events are any fever greater than or equal to (&gt;=) 37.5 degrees Celsius [C], fatigue, headache, chills, rash, vomiting, decreased appetite, new muscle pain, aggravated muscle pain, new joint pain, aggravated joint pain, use of medication to treat fever and use of medication to treat pain. All reports of fever &gt;=39 degrees C in 13vPnC and 23vPS were confirmed as data entry errors.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">764</enrollment>
  <condition>Pneumococcal Vaccines</condition>
  <condition>Pneumococcal Conjugate Vaccine</condition>
  <arm_group>
    <arm_group_label>&gt;= 65-year age group-13vPnC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>&gt;= 65-year age group-23vPS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-valent pneumococcal conjugate vaccine</intervention_name>
    <description>A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.</description>
    <arm_group_label>&gt;= 65-year age group-13vPnC</arm_group_label>
    <other_name>13vPnC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>23-valent pneumococcal polysaccharide vaccine</intervention_name>
    <description>A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.</description>
    <arm_group_label>&gt;= 65-year age group-23vPS</arm_group_label>
    <other_name>23VPS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy Japanese male and female adults aged 65 years old and older at time of
             enrollment. Subjects with preexisting stable disease, defined as disease not requiring
             significant change in therapy or hospitalization for worsening disease 12 weeks before
             receipt of the study vaccine, are eligible.

          2. Male and female subjects of childbearing potential must agree to use a highly
             effective method of contraception throughout the study or for at least 28 days after
             the last dose of the study vaccine whichever is longer.

        Exclusion Criteria:

          1. History of severe adverse reaction including hypersensitivity such as anaphylaxis
             associated with a vaccine or vaccine component.

          2. Previous vaccination with any licensed or experimental pneumococcal vaccine.

          3. Documented Streptococcus pneumoniae infection within the past 5 years.

          4. Residence in a nursing home, long-term care facility, or other institution or
             requirement of semiskilled nursing care.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seishinkai Inoue Hospital</name>
      <address>
        <city>Itoshima</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama Minoru Clinic</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oda Clinic</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sone Clinic</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Co. LTA Sumida Hospital</name>
      <address>
        <city>Sumida-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Co.LTA PS Clinic</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uzumasa Medical Clinic</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Senbon Hospital</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1851088&amp;StudyName=A%20Phase%203%20Trial%20Evaluating%20the%20Safety%2C%20Tolerability%2C%20and%20Immunogenicity%20of%20a%2013-valent%20Pneumococcal%20Conjugate%20Vaccine%20in%20Japanese%20Elde</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2012</study_first_submitted>
  <study_first_submitted_qc>July 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2012</study_first_posted>
  <results_first_submitted>July 17, 2013</results_first_submitted>
  <results_first_submitted_qc>July 17, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 20, 2013</results_first_posted>
  <last_update_submitted>July 17, 2013</last_update_submitted>
  <last_update_submitted_qc>July 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>13VPNC</keyword>
  <keyword>23VPS</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>13vPnC</title>
          <description>13-valent pneumococcal conjugate vaccine (13vPnC) administered as a 0.5 milliliter (mL) single dose intramuscularly on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>23vPS</title>
          <description>23-valent pneumococcal polysaccharide vaccine (23vPS) administered as a 0.5 mL single dose intramuscularly on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="382"/>
                <participants group_id="P2" count="382"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="381"/>
                <participants group_id="P2" count="382"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>13vPnC</title>
          <description>13-valent pneumococcal conjugate vaccine (13vPnC) administered as a 0.5 milliliter (mL) single dose intramuscularly on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>23vPS</title>
          <description>23-valent pneumococcal polysaccharide vaccine (23vPS) administered as a 0.5 mL single dose intramuscularly on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="382"/>
            <count group_id="B2" value="382"/>
            <count group_id="B3" value="764"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.0" spread="4.08"/>
                    <measurement group_id="B2" value="69.7" spread="3.66"/>
                    <measurement group_id="B3" value="69.9" spread="3.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="198"/>
                    <measurement group_id="B2" value="187"/>
                    <measurement group_id="B3" value="385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="184"/>
                    <measurement group_id="B2" value="195"/>
                    <measurement group_id="B3" value="379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for 12 Common Serotypes 1 Month After Vaccination</title>
        <description>Antibody-mediated serum OPA against each of the 12 pneumococcal serotypes (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) was measured centrally using a quantitative functional microcolony OPA (mcOPA) assay. Results were expressed as OPA titers. OPA titers were logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs).</description>
        <time_frame>One month after vaccination</time_frame>
        <population>Evaluable immunogenicity population:eligible participants, received study vaccine to which randomized, received no prohibited vaccines, had at least 1 valid and determinate assay result, had blood drawn within prescribed time frame and had no major protocol violations. n= number of participants with determinate OPA antibody titer to given serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) administered as a 0.5 milliliter (mL) single dose intramuscularly on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>23vPS</title>
            <description>23-valent pneumococcal polysaccharide vaccine (23vPS) administered as a 0.5 mL single dose intramuscularly on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for 12 Common Serotypes 1 Month After Vaccination</title>
          <description>Antibody-mediated serum OPA against each of the 12 pneumococcal serotypes (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) was measured centrally using a quantitative functional microcolony OPA (mcOPA) assay. Results were expressed as OPA titers. OPA titers were logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs).</description>
          <population>Evaluable immunogenicity population:eligible participants, received study vaccine to which randomized, received no prohibited vaccines, had at least 1 valid and determinate assay result, had blood drawn within prescribed time frame and had no major protocol violations. n= number of participants with determinate OPA antibody titer to given serotype.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="366"/>
                <count group_id="O2" value="367"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 (n=366, 366)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103" lower_limit="84.6" upper_limit="125.5"/>
                    <measurement group_id="O2" value="78" lower_limit="63.6" upper_limit="95.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 (n=365, 367)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" lower_limit="38.1" upper_limit="51.5"/>
                    <measurement group_id="O2" value="61" lower_limit="52.8" upper_limit="70.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 (n=360, 362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1016" lower_limit="850.7" upper_limit="1213.2"/>
                    <measurement group_id="O2" value="392" lower_limit="314.7" upper_limit="487.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 (n=350, 361)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="347" lower_limit="282.3" upper_limit="425.6"/>
                    <measurement group_id="O2" value="118" lower_limit="98.4" upper_limit="142.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6B (n=360, 359)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1995" lower_limit="1689.3" upper_limit="2355.9"/>
                    <measurement group_id="O2" value="1440" lower_limit="1223.5" upper_limit="1694.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7F (n=365, 364)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1901" lower_limit="1642.8" upper_limit="2198.7"/>
                    <measurement group_id="O2" value="1361" lower_limit="1153.3" upper_limit="1605.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9V (n=365,358)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="858" lower_limit="675.7" upper_limit="1089.5"/>
                    <measurement group_id="O2" value="379" lower_limit="290.2" upper_limit="493.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14 (n=363, 359)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1028" lower_limit="866.9" upper_limit="1217.9"/>
                    <measurement group_id="O2" value="1059" lower_limit="896.6" upper_limit="1250.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18C (n=366, 362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2015" lower_limit="1675.4" upper_limit="2424.5"/>
                    <measurement group_id="O2" value="938" lower_limit="752.7" upper_limit="1170.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>19A (n=365, 362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="985" lower_limit="841.5" upper_limit="1153.9"/>
                    <measurement group_id="O2" value="429" lower_limit="358.0" upper_limit="513.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>19F (n=352, 357)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="773" lower_limit="607.9" upper_limit="983.0"/>
                    <measurement group_id="O2" value="388" lower_limit="305.6" upper_limit="491.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23F (n=366, 363)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="456" lower_limit="363.7" upper_limit="570.6"/>
                    <measurement group_id="O2" value="180" lower_limit="143.1" upper_limit="226.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 1: CI for the GMT ratio was calculated by the back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC – 23vPS).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was to be concluded if the lower bound of the 2-sided 95% CI was greater than 0.5.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 3: CI for the GMT ratio was calculated by the back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC – 23vPS).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was to be concluded if the lower bound of the 2-sided 95% CI was greater than 0.5.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>0.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 4: CI for the GMT ratio was calculated by the back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC – 23vPS).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was to be concluded if the lower bound of the 2-sided 95% CI was greater than 0.5.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.96</ci_lower_limit>
            <ci_upper_limit>3.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 5: CI for the GMT ratio was calculated by the back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC – 23vPS).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was to be concluded if the lower bound of the 2-sided 95% CI was greater than 0.5.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>2.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.22</ci_lower_limit>
            <ci_upper_limit>3.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6B: CI for the GMT ratio was calculated by the back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC – 23vPS).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was to be concluded if the lower bound of the 2-sided 95% CI was greater than 0.5.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.10</ci_lower_limit>
            <ci_upper_limit>1.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 7F: CI for the GMT ratio was calculated by the back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC – 23vPS).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was to be concluded if the lower bound of the 2-sided 95% CI was greater than 0.5.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.12</ci_lower_limit>
            <ci_upper_limit>1.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 9V: CI for the GMT ratio was calculated by the back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC – 23vPS).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was to be concluded if the lower bound of the 2-sided 95% CI was greater than 0.5.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.59</ci_lower_limit>
            <ci_upper_limit>3.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 14: CI for the GMT ratio was calculated by the back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC – 23vPS).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was to be concluded if the lower bound of the 2-sided 95% CI was greater than 0.5.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 18C: CI for the GMT ratio was calculated by the back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC – 23vPS).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was to be concluded if the lower bound of the 2-sided 95% CI was greater than 0.5.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.61</ci_lower_limit>
            <ci_upper_limit>2.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19A: CI for the GMT ratio was calculated by the back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC – 23vPS).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was to be concluded if the lower bound of the 2-sided 95% CI was greater than 0.5.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.81</ci_lower_limit>
            <ci_upper_limit>2.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19F: CI for the GMT ratio was calculated by the back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC – 23vPS).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was to be concluded if the lower bound of the 2-sided 95% CI was greater than 0.5.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.42</ci_lower_limit>
            <ci_upper_limit>2.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 23F: CI for the GMT ratio was calculated by the back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC – 23vPS).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was to be concluded if the lower bound of the 2-sided 95% CI was greater than 0.5.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.84</ci_lower_limit>
            <ci_upper_limit>3.49</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving At Least a 4-fold Rise in OPA Titers for Serotype 6A 1 Month After Vaccination</title>
        <description>For serotype 6A the percentage of participants achieving at least a 4-fold rise on the serotype-specific antibody titer from pre-vaccination to 1 month post-vaccination was computed along with exact, 2-sided 95% confidence interval for the proportion.</description>
        <time_frame>One month after vaccination</time_frame>
        <population>Evaluable immunogenicity population. Here ‘N’ (number of participants analyzed) signifies participants with determinate fold rise of OPA antibody titer to serotype 6A.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) administered as a 0.5 milliliter (mL) single dose intramuscularly on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>23vPS</title>
            <description>23-valent pneumococcal polysaccharide vaccine (23vPS) administered as a 0.5 mL single dose intramuscularly on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving At Least a 4-fold Rise in OPA Titers for Serotype 6A 1 Month After Vaccination</title>
          <description>For serotype 6A the percentage of participants achieving at least a 4-fold rise on the serotype-specific antibody titer from pre-vaccination to 1 month post-vaccination was computed along with exact, 2-sided 95% confidence interval for the proportion.</description>
          <population>Evaluable immunogenicity population. Here ‘N’ (number of participants analyzed) signifies participants with determinate fold rise of OPA antibody titer to serotype 6A.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="319"/>
                <count group_id="O2" value="320"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.0" lower_limit="68.8" upper_limit="78.7"/>
                    <measurement group_id="O2" value="47.2" lower_limit="41.6" upper_limit="52.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference in proportions (13vPnC – 23vPS) expressed as a percentage presented along with exact, 2-sided 95%CI. Statistical significance was to be concluded if the lower bound of the 2-sided 95% CI was greater than 0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in percentage</param_type>
            <param_value>26.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>19.3</ci_lower_limit>
            <ci_upper_limit>34.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for 12 Common Serotypes and Serotype 6A 1 Month After Vaccination</title>
        <description>Antibody-mediated serum OPA against each of the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) was measured centrally using a quantitative functional microcolonoy OPA (mcOPA) assay. Results were expressed as OPA titers. OPA titers were logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs).</description>
        <time_frame>One month after vaccination</time_frame>
        <population>Evaluable immunogenicity population:eligible participants, received study vaccine to which randomized, received no prohibited vaccines, had at least 1 valid and determinate assay result, had blood drawn within prescribed time frame and had no major protocol violations. n= number of participants with determinate OPA antibody titer to given serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) administered as a 0.5 milliliter (mL) single dose intramuscularly on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>23vPS</title>
            <description>23-valent pneumococcal polysaccharide vaccine (23vPS) administered as a 0.5 mL single dose intramuscularly on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for 12 Common Serotypes and Serotype 6A 1 Month After Vaccination</title>
          <description>Antibody-mediated serum OPA against each of the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) was measured centrally using a quantitative functional microcolonoy OPA (mcOPA) assay. Results were expressed as OPA titers. OPA titers were logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs).</description>
          <population>Evaluable immunogenicity population:eligible participants, received study vaccine to which randomized, received no prohibited vaccines, had at least 1 valid and determinate assay result, had blood drawn within prescribed time frame and had no major protocol violations. n= number of participants with determinate OPA antibody titer to given serotype.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="366"/>
                <count group_id="O2" value="367"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 (n=366, 366)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103" lower_limit="84.6" upper_limit="125.5"/>
                    <measurement group_id="O2" value="78" lower_limit="63.6" upper_limit="95.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 (n=365, 367)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" lower_limit="38.1" upper_limit="51.5"/>
                    <measurement group_id="O2" value="61" lower_limit="52.8" upper_limit="70.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 (n=360, 362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1016" lower_limit="850.7" upper_limit="1213.2"/>
                    <measurement group_id="O2" value="392" lower_limit="314.7" upper_limit="487.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 (n=350, 361)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="347" lower_limit="282.3" upper_limit="425.6"/>
                    <measurement group_id="O2" value="118" lower_limit="98.4" upper_limit="142.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6B (n=360, 359)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1995" lower_limit="1689.3" upper_limit="2355.9"/>
                    <measurement group_id="O2" value="1440" lower_limit="1223.5" upper_limit="1694.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7F (n=365, 364)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1901" lower_limit="1642.8" upper_limit="2198.7"/>
                    <measurement group_id="O2" value="1361" lower_limit="1153.3" upper_limit="1605.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9V (n=365,358)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="858" lower_limit="675.7" upper_limit="1089.5"/>
                    <measurement group_id="O2" value="379" lower_limit="290.2" upper_limit="493.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14 (n=363, 359)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1028" lower_limit="866.9" upper_limit="1217.9"/>
                    <measurement group_id="O2" value="1059" lower_limit="896.6" upper_limit="1250.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18C (n=366, 362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2015" lower_limit="1675.4" upper_limit="2424.5"/>
                    <measurement group_id="O2" value="938" lower_limit="752.7" upper_limit="1170.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>19A (n=365, 362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="985" lower_limit="841.5" upper_limit="1153.9"/>
                    <measurement group_id="O2" value="429" lower_limit="358.0" upper_limit="513.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>19F (n=352, 357)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="773" lower_limit="607.9" upper_limit="983.0"/>
                    <measurement group_id="O2" value="388" lower_limit="305.6" upper_limit="491.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23F (n=366, 363)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="456" lower_limit="363.7" upper_limit="570.6"/>
                    <measurement group_id="O2" value="180" lower_limit="143.1" upper_limit="226.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6A (n=360, 349)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2122" lower_limit="1790.9" upper_limit="2515.2"/>
                    <measurement group_id="O2" value="676" lower_limit="542.4" upper_limit="841.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 1: CI for the GMT ratio was calculated by the back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC – 23vPS). Statistical significance was to be concluded if the lower bound of the 2-sided 95% CI was greater than 1.0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT Ratio</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 3: CI for the GMT ratio was calculated by the back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC – 23vPS). Statistical significance was to be concluded if the lower bound of the 2-sided 95% CI was greater than 1.0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT Ratio</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>0.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 4: CI for the GMT ratio was calculated by the back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC – 23vPS). Statistical significance was to be concluded if the lower bound of the 2-sided 95% CI was greater than 1.0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT Ratio</param_type>
            <param_value>2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.96</ci_lower_limit>
            <ci_upper_limit>3.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 5: CI for the GMT ratio was calculated by the back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC – 23vPS). Statistical significance was to be concluded if the lower bound of the 2-sided 95% CI was greater than 1.0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT Ratio</param_type>
            <param_value>2.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.22</ci_lower_limit>
            <ci_upper_limit>3.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6B: CI for the GMT ratio was calculated by the back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC – 23vPS). Statistical significance was to be concluded if the lower bound of the 2-sided 95% CI was greater than 1.0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT Ratio</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.10</ci_lower_limit>
            <ci_upper_limit>1.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 7F: CI for the GMT ratio was calculated by the back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC – 23vPS). Statistical significance was to be concluded if the lower bound of the 2-sided 95% CI was greater than 1.0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT Ratio</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.12</ci_lower_limit>
            <ci_upper_limit>1.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 9V: CI for the GMT ratio was calculated by the back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC – 23vPS). Statistical significance was to be concluded if the lower bound of the 2-sided 95% CI was greater than 1.0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT Ratio</param_type>
            <param_value>2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.59</ci_lower_limit>
            <ci_upper_limit>3.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 14: CI for the GMT ratio was calculated by the back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC – 23vPS). Statistical significance was to be concluded if the lower bound of the 2-sided 95% CI was greater than 1.0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT Ratio</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 18C: CI for the GMT ratio was calculated by the back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC – 23vPS). Statistical significance was to be concluded if the lower bound of the 2-sided 95% CI was greater than 1.0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT Ratio</param_type>
            <param_value>2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.61</ci_lower_limit>
            <ci_upper_limit>2.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19A: CI for the GMT ratio was calculated by the back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC – 23vPS). Statistical significance was to be concluded if the lower bound of the 2-sided 95% CI was greater than 1.0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT Ratio</param_type>
            <param_value>2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.81</ci_lower_limit>
            <ci_upper_limit>2.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19F: CI for the GMT ratio was calculated by the back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC – 23vPS). Statistical significance was to be concluded if the lower bound of the 2-sided 95% CI was greater than 1.0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT Ratio</param_type>
            <param_value>2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.42</ci_lower_limit>
            <ci_upper_limit>2.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 23F: CI for the GMT ratio was calculated by the back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC – 23vPS). Statistical significance was to be concluded if the lower bound of the 2-sided 95% CI was greater than 1.0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT Ratio</param_type>
            <param_value>2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.84</ci_lower_limit>
            <ci_upper_limit>3.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6A: CI for the GMT ratio was calculated by the back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC – 23vPS). Statistical significance was to be concluded if the lower bound of the 2-sided 95% CI was greater than 2.0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT Ratio</param_type>
            <param_value>3.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.38</ci_lower_limit>
            <ci_upper_limit>4.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination</title>
        <description>Local reactions reported using an electronic diary. Redness and swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters [cm]; Moderate (5.1 to 10.0 cm); Severe (&gt;10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).</description>
        <time_frame>Within 14 days after vaccination</time_frame>
        <population>Safety population included all participants who received the study vaccine. 'N' (number of participants analyzed)=participants with known values for any local reaction. 'n'=number of participants with known values for specified local reaction for each group respectively. Participants may be represented in more than 1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) administered as a 0.5 milliliter (mL) single dose intramuscularly on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>23vPS</title>
            <description>23-valent pneumococcal polysaccharide vaccine (23vPS) administered as a 0.5 mL single dose intramuscularly on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination</title>
          <description>Local reactions reported using an electronic diary. Redness and swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters [cm]; Moderate (5.1 to 10.0 cm); Severe (&gt;10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).</description>
          <population>Safety population included all participants who received the study vaccine. 'N' (number of participants analyzed)=participants with known values for any local reaction. 'n'=number of participants with known values for specified local reaction for each group respectively. Participants may be represented in more than 1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness: Any (n=355, 363)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.7" lower_limit="24.1" upper_limit="33.7"/>
                    <measurement group_id="O2" value="10.5" lower_limit="7.5" upper_limit="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild (n=352, 362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2" lower_limit="17.9" upper_limit="26.9"/>
                    <measurement group_id="O2" value="7.7" lower_limit="5.2" upper_limit="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate (n=353, 360)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" lower_limit="13.5" upper_limit="21.6"/>
                    <measurement group_id="O2" value="3.9" lower_limit="2.1" upper_limit="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe (n=349, 359)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="1.8" upper_limit="5.9"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.0" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any (n=353, 360)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5" lower_limit="17.4" upper_limit="26.2"/>
                    <measurement group_id="O2" value="6.7" lower_limit="4.3" upper_limit="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild (n=351, 360)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" lower_limit="12.8" upper_limit="20.8"/>
                    <measurement group_id="O2" value="5.0" lower_limit="3.0" upper_limit="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate (n=351, 359)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" lower_limit="6.8" upper_limit="13.3"/>
                    <measurement group_id="O2" value="2.5" lower_limit="1.2" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe (n=349, 359)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.5" upper_limit="3.3"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.0" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Any (n=362, 368)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.6" lower_limit="40.4" upper_limit="50.9"/>
                    <measurement group_id="O2" value="38.3" lower_limit="33.3" upper_limit="43.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Mild (n=362, 368)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.3" lower_limit="40.1" upper_limit="50.6"/>
                    <measurement group_id="O2" value="37.5" lower_limit="32.5" upper_limit="42.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Moderate (n=349, 361)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="1.4" upper_limit="5.2"/>
                    <measurement group_id="O2" value="5.5" lower_limit="3.4" upper_limit="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Severe (n=348, 359)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="1.1"/>
                    <measurement group_id="O2" value="1.4" lower_limit="0.5" upper_limit="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Any (n=355, 362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3" lower_limit="12.6" upper_limit="20.6"/>
                    <measurement group_id="O2" value="16.9" lower_limit="13.1" upper_limit="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Mild (n=355, 361)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" lower_limit="11.9" upper_limit="19.7"/>
                    <measurement group_id="O2" value="15.8" lower_limit="12.2" upper_limit="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Moderate(n=348, 360)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.3" upper_limit="2.9"/>
                    <measurement group_id="O2" value="3.6" lower_limit="1.9" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Severe (n=348, 359)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.0" upper_limit="1.6"/>
                    <measurement group_id="O2" value="1.7" lower_limit="0.6" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination</title>
        <description>Systemic events reported using an electronic diary. Systemic events are any fever greater than or equal to (&gt;=) 37.5 degrees Celsius [C], fatigue, headache, chills, rash, vomiting, decreased appetite, new muscle pain, aggravated muscle pain, new joint pain, aggravated joint pain, use of medication to treat fever and use of medication to treat pain. All reports of fever &gt;=39 degrees C in 13vPnC and 23vPS were confirmed as data entry errors.</description>
        <time_frame>Within 14 days after vaccination</time_frame>
        <population>Safety population included all participants who received the study vaccine. 'N' (number of participants analyzed)=participants with known values for any systemic events. 'n'=number of participants with known values for specified systemic events for each group respectively. Participants may be represented in more than 1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) administered as a 0.5 milliliter (mL) single dose intramuscularly on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>23vPS</title>
            <description>23-valent pneumococcal polysaccharide vaccine (23vPS) administered as a 0.5 mL single dose intramuscularly on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination</title>
          <description>Systemic events reported using an electronic diary. Systemic events are any fever greater than or equal to (&gt;=) 37.5 degrees Celsius [C], fatigue, headache, chills, rash, vomiting, decreased appetite, new muscle pain, aggravated muscle pain, new joint pain, aggravated joint pain, use of medication to treat fever and use of medication to treat pain. All reports of fever &gt;=39 degrees C in 13vPnC and 23vPS were confirmed as data entry errors.</description>
          <population>Safety population included all participants who received the study vaccine. 'N' (number of participants analyzed)=participants with known values for any systemic events. 'n'=number of participants with known values for specified systemic events for each group respectively. Participants may be represented in more than 1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="357"/>
                <count group_id="O2" value="366"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever &gt;=37.5 to &lt;38.5 degrees C (n=348, 359)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="1.2" upper_limit="4.9"/>
                    <measurement group_id="O2" value="2.8" lower_limit="1.3" upper_limit="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;=38.5 to &lt;39 degrees C (n=348, 359)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.0" upper_limit="1.6"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.0" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;=39 to &lt;=40 degrees C (n=348, 359)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="1.1"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.1" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;40 degrees C (n=348, 359)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.2" upper_limit="2.5"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (n=352, 362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" lower_limit="13.5" upper_limit="21.7"/>
                    <measurement group_id="O2" value="16.0" lower_limit="12.4" upper_limit="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (n=351, 361)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" lower_limit="6.6" upper_limit="12.9"/>
                    <measurement group_id="O2" value="11.6" lower_limit="8.5" upper_limit="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills (n=348, 359)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="1.4" upper_limit="5.2"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.3" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (n=350, 359)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" lower_limit="6.1" upper_limit="12.3"/>
                    <measurement group_id="O2" value="3.6" lower_limit="1.9" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (n=348, 359)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.3" upper_limit="2.9"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.1" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite (n=348, 360)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="2.0" upper_limit="6.3"/>
                    <measurement group_id="O2" value="5.0" lower_limit="3.0" upper_limit="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New muscle pain (n=354, 362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" lower_limit="14.5" upper_limit="22.8"/>
                    <measurement group_id="O2" value="17.4" lower_limit="13.6" upper_limit="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated muscle pain (n=350, 359)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="2.2" upper_limit="6.6"/>
                    <measurement group_id="O2" value="3.9" lower_limit="2.1" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New joint pain (n=350, 359)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" lower_limit="5.1" upper_limit="11.0"/>
                    <measurement group_id="O2" value="7.0" lower_limit="4.6" upper_limit="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated joint pain (n=349, 359)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="1.4" upper_limit="5.2"/>
                    <measurement group_id="O2" value="3.1" lower_limit="1.5" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of medication to treat fever (n=348, 360)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.2" upper_limit="2.5"/>
                    <measurement group_id="O2" value="2.2" lower_limit="1.0" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of medication to treat pain (n=348, 360)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.3" upper_limit="2.9"/>
                    <measurement group_id="O2" value="2.8" lower_limit="1.3" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs/SAEs: recorded from signing of informed consent form to completion of study. Participants recorded pre-specified AEs in electronic diary:local reactions; systemic events; use of antipyretic medication (up to 14 days after vaccination).</time_frame>
      <desc>SAEs and AEs were grouped by system organ class and summarized. AEs included AEs collected in the electronic diary (local and systemic reactions; systematic assessment) and AEs collected on the case report form at each visit (nonsystematic assessment).</desc>
      <group_list>
        <group group_id="E1">
          <title>13vPnC</title>
          <description>13-valent pneumococcal conjugate vaccine (13vPnC) administered as a 0.5 milliliter (mL) single dose intramuscularly on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>23vPS</title>
          <description>23-valent pneumococcal polysaccharide vaccine (23vPS) administered as a 0.5 mL single dose intramuscularly on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="211" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="166" subjects_at_risk="382"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Periodontal disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Vaccination site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;=37.5 to &lt;38.5 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title vocab="Syetemic Events">Fever &gt;=38.5 to &lt;39 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;=39 to &lt;=40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>All reports of fever &gt;=39 degrees C in 13vPnC and 23vPS were confirmed as data entry errors.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>All reports of fever &gt;=39 degrees C in 13vPnC and 23vPS were confirmed as data entry errors.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fatigue</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Headache</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Chills</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Rash</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="350"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Vomiting</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">New muscle pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="354"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Aggravated muscle pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="350"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">New joint pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="350"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Aggravated joint pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="349"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Conjunctivitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Lip injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Intercostal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Haemorrhage subcutaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Prurigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title vocab="Local Reaction">Redness (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title vocab="Local Reaction">Redness (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title vocab="Local Reaction">Redness (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title vocab="Local Reaction">Redness (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="349"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title vocab="Local Reaction">Swelling (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title vocab="Local Reaction">Swelling (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Swelling (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Swelling (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="349"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Pain (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="165" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="141" subjects_at_risk="368"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Pain (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="164" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="138" subjects_at_risk="368"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Pain (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="349"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Pain (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Limitation of arm movement (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Limitation of arm movement (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="361"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Limitation of arm movement (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="360"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Limitation of arm movement (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

